Esperion Therapeutics (ESPR) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Esperion Therapeutics Revenue Highlights


Latest Revenue (Y)

$116.33M

Latest Revenue (Q)

$73.83M

Main Segment (Y)

Product

Esperion Therapeutics Revenue by Period


Esperion Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$116.33M54.14%
2022-12-31$75.47M-3.79%
2021-12-31$78.45M-65.52%
2020-12-31$227.55M53.37%
2019-12-31$148.36M-19.57%
2018-12-31$184.47M100.00%
2017-12-31-100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31--100.00%
2013-12-31$4.98B100.00%
2012-12-31-100.00%
2011-12-31-100.00%
2002-12-31-100.00%
2001-12-31--100.00%
2000-12-31$2.00K100.00%
1999-12-31--

Esperion Therapeutics generated $116.33M in revenue during NA 2023, up 54.14% compared to the previous quarter, and up 63.06% compared to the same period a year ago.

Esperion Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30$73.83M-46.39%
2024-03-31$137.74M327.09%
2023-12-31$32.25M-5.06%
2023-09-30$33.97M31.73%
2023-06-30$25.79M5.99%
2023-03-31$24.33M29.29%
2022-12-31$18.82M-0.85%
2022-09-30$18.98M0.74%
2022-06-30$18.84M0.03%
2022-03-31$18.84M22.30%
2021-12-31$15.40M6.88%
2021-09-30$14.41M-64.56%
2021-06-30$40.66M409.64%
2021-03-31$7.98M-17.22%
2020-12-31$9.64M151.45%
2020-09-30$3.83M-98.19%
2020-06-30$212.24M11434.57%
2020-03-31$1.84M87.37%
2019-12-31$982.00K0.10%
2019-09-30$981.00K-0.10%
2019-06-30$982.00K-99.32%
2019-03-31$145.42M-21.17%
2018-12-31$184.47M100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31-100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-12-31-100.00%
2012-09-30-100.00%
2012-06-30-100.00%
2012-03-31-100.00%
2003-09-30-100.00%
2003-06-30-100.00%
2003-03-31-100.00%
2002-12-31-100.00%
2002-09-30-100.00%
2002-06-30-100.00%
2002-03-31-100.00%
2001-12-31-100.00%
2001-09-30--100.00%
2001-06-30$1.00K-
2001-03-31$1.00K-
2000-12-31$1.00K-
2000-09-30$1.00K-
2000-06-30$1.00K100.00%
2000-03-31--

Esperion Therapeutics generated $73.83M in revenue during Q2 2024, up -46.39% compared to the previous quarter, and up 303.48% compared to the same period a year ago.

Esperion Therapeutics Revenue Breakdown


Esperion Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Product$78.33M$55.86M---
Collaboration Revenue$38.00M$19.61M$38.40M$214.58M-
Royalty Revenue From DSE--$9.90M--
Ongoing Regulatory And Development Activities Revenue---$1.60M$4.00M
Product Sales Bulk Tablets And Royalty Revenue Of Nilemdo And Nustendi---$2.80M-
Milestone Marketing Authorization Approval Nustendi---$150.00M-
License For Intellectual Property Revenue----$144.40M

Esperion Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (67.34%), and Collaboration Revenue (32.66%).

Quarterly Revenue by Product

Product/ServiceMar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
Collaboration Revenue$112.98M$11.49M$13.72M$5.49M$7.30M$3.85M$5.02M$5.26M$5.48M$3.21M$3.51M$30.05M$1.63M$1.47M$502.00K$211.63M$982.00K---
Product$24.76M$20.76M$20.25M$20.29M$17.03M$14.97M$12.19M$8.17M------------
Royalty Revenue And Product Sales Bulk Tablets------$4.40M$5.00M$5.30M$3.30M----------
Royalty Revenue And Product Sales Bulk Tablets Nilemdo And Nustendi-----------$2.00M--------
Product Sales Bulk Tablets Nilemdo And Nustendi------------$1.60M$500.00K$1.00M-----
Milestone Marketing Authorization Approval Nustendi---------------$150.00M----
Regulatory Performance Obligations---------------$700.00K----
Ongoing Regulatory Activities Revenue----------------$1.00M---
Ongoing Regulatory And Development Activities Revenue-----------------$1.00M$1.00M$1.00M
License For Intellectual Property Revenue--------------------

Esperion Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Collaboration Revenue (82.03%), and Product (17.97%).

Esperion Therapeutics Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
ELANElanco Animal Health$4.42B$1.21B
CTLTCatalent$4.38B$1.07B
NBIXNeurocrine Biosciences$1.89B$622.10M
ALKSAlkermes$1.66B$378.14M
PBHPrestige Consumer Healthcare$1.13B$267.14M
PAHCPhibro Animal Health$977.89M$263.22M
PCRXPacira BioSciences$674.98M$178.02M
COLLCollegium Pharmaceutical$566.77M$144.92M
ANIPANI Pharmaceuticals$486.82M$138.04M
ITCIIntra-Cellular Therapies$462.18M$175.38M
IRWDIronwood Pharmaceuticals$442.74M$94.40M
EGRXEagle Pharmaceuticals$316.61M$64.65M
DCPHDeciphera Pharmaceuticals$163.36M$45.00M
KMDAKamada$144.76M$37.40M
SIGASIGA$139.92M$21.81M
LFCRLifecore Biomedical$128.26M$24.70M
ESPREsperion Therapeutics$116.33M$73.83M
RMTIRockwell Medical$83.61M$22.68M
AVDLAvadel Pharmaceuticals$27.96M$41.50M
AGRXAgile Therapeutics$19.59M$5.58M

ESPR Revenue FAQ


Esperion Therapeutics's yearly revenue for 2023 was $116.33M, representing an increase of 54.14% compared to 2022. The company's yearly revenue for 2022 was $75.48M, representing a decrease of -3.79% compared to 2021. ESPR's yearly revenue for 2021 was $78.45M, representing a decrease of -65.52% compared to 2020.

Esperion Therapeutics's quarterly revenue for Q2 2024 was $73.83M, a -46.39% decrease from the previous quarter (Q1 2024), and a 186.33% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $137.74M, a 327.09% increase from the previous quarter (Q4 2023), and a 466.14% increase year-over-year (Q1 2023). ESPR's quarterly revenue for Q4 2023 was $32.25M, a -5.06% decrease from the previous quarter (Q3 2023), and a 71.38% increase year-over-year (Q4 2022).

Esperion Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 48.30%, and for the last 5 years (2019-2023) was -21.59%.

Esperion Therapeutics's revenue streams in c 23 are Product, and Collaboration Revenue. Product generated $78.34M in revenue, accounting 67.34% of the company's total revenue, up 40.23% year-over-year. Collaboration Revenue generated $38M in revenue, accounting 32.66% of the company's total revenue, up 93.75% year-over-year.

For the fiscal year ending Dec 23, the largest source of revenue of Esperion Therapeutics was Product. This segment made a revenue of $78.34M, representing 67.34% of the company's total revenue.